NeomiVac - NeoVac
Alternative Names: mRNA-LNP SARS-CoV-2 vaccine - NeoVacLatest Information Update: 27 May 2024
At a glance
- Originator NeoVac
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 03 May 2024 Preclinical trials in COVID-2019 infections (Prevention) in United Kingdom (IM) before May 2024
- 03 May 2024 NeoVac plans a phase I trial for COVID-2019 infections (Prevention) in United Kingdom (IM, Injection) in May 2024 (ISRCTN13564930)
- 24 Nov 2023 Phase-I clinical trials in COVID-2019 infections (Prevention, In adults) in United Kingdom (IM) (ISRCTN13564930)